UPMC Enterprises

Novasenta is a pharmaceutical company focused on developing innovative immunotherapy treatments for cancer. Founded in 2018 and headquartered in Pittsburgh, Pennsylvania, the company employs a systematic and rigorous approach to analyze human tumor microenvironments, aiming to uncover new druggable targets. By utilizing single-cell level analysis of high-quality human tumor samples and advanced data mining techniques, Novasenta accelerates the transition from discovery to patient-ready therapies. The company specializes in immuno-oncology therapeutics, leveraging a machine-learning-enabled platform to identify immune networks and potential drug targets within the tumor microenvironment. Through its research efforts, Novasenta seeks to provide patients with safer and more effective cancer treatments.